324 related articles for article (PubMed ID: 21251382)
21. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Warner JL
BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
[No Abstract] [Full Text] [Related]
22. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
[TBL] [Abstract][Full Text] [Related]
23. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
[TBL] [Abstract][Full Text] [Related]
24. [More quality of life again with tolterodine].
Praxis (Bern 1994); 2006 Oct; 95(42):1636. PubMed ID: 17111848
[No Abstract] [Full Text] [Related]
25. The effects of reformulation: improved therapeutic index.
MacDiarmid S; Sandage BW; Malhotra BK
Curr Urol Rep; 2008 Nov; 9(6):465-71. PubMed ID: 18947511
[TBL] [Abstract][Full Text] [Related]
26. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Speakman MJ
Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
[No Abstract] [Full Text] [Related]
27. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Dmochowski R
Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
[No Abstract] [Full Text] [Related]
28. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
29. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
[TBL] [Abstract][Full Text] [Related]
30. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
[TBL] [Abstract][Full Text] [Related]
31. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.
Armstrong RB; Luber KM; Peters KM
Int Urol Nephrol; 2005; 37(2):247-52. PubMed ID: 16142551
[TBL] [Abstract][Full Text] [Related]
32. Clinical experiences with tolterodine.
Nilvebrant L
Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
[TBL] [Abstract][Full Text] [Related]
33. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
[TBL] [Abstract][Full Text] [Related]
34. Detrol LA and Diropan XL for overactive bladder.
Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
[No Abstract] [Full Text] [Related]
35. Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
Gomes T; Juurlink DN; Ho JM; Schneeweiss S; Mamdani MM
J Urol; 2011 Oct; 186(4):1340-4. PubMed ID: 21855905
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
[TBL] [Abstract][Full Text] [Related]
37. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
Kaplan SA; Schneider T; Foote JE; Guan Z; Carlsson M; Gong J
BJU Int; 2011 May; 107(9):1432-40. PubMed ID: 20860717
[TBL] [Abstract][Full Text] [Related]
38. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
[TBL] [Abstract][Full Text] [Related]
40. The newer antimuscarinic drugs: bladder control with less dry mouth.
Appell RA
Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
